Immunovia Publishes Full Year Report for 2024

October-December 2024 · Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). · Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc. · Operating losses were -30,1 MSEK (-23,4). · Earnings per share before and after dilution were 0.02 SEK (-1,08). · Cash flow from operating activities amounted to -28,3 MSEK (-28,5). · Cash and cash equivalents at end of period equaled 25,3 MSEK (76,8). · On October 2, the company